Evaluating the efficacy of Bemcentinib (BGB) in modulating Axl activity in the brain of the rNLS8 inducible mouse model of ALS
- 1Center for Neurodegenerative Disease Research (CNDR), Department of Pathology and Laboratory Medicine, Perelman School of Medicine, University of Pennsylvania
Abstract
Amyotrophic lateral sclerosis (ALS) is characterized by progressive degeneration of upper and lower motor neurons and pathological accumulation of TAR DNA-binding protein 43 (TDP-43). Microglial activation is a prominent feature of ALS pathology, and the receptor tyrosine kinase Axl, a marker of disease-associated microglia (DAM), has been proposed as a potential therapeutic target. Here, we investigated Axl signaling and its pharmacological inhibition in the inducible rNLS8 mouse model of ALS. Disease progression in the brain of these mice was accompanied by robust microgliosis, reflected by increased Iba1 Immunoreactivity in the hippocampus and by elevated Axl protein at later stages. Treatment with Bemcentinib (BGB), a selective Axl inhibitor, resulted in central nervous system penetration by the drug and evidence of target engagement as revealed by increased plasma soluble Axl and modulation of downstream signaling pathways in the brain, including reduced total Stat3 and Akt. Nevertheless, BGB administration failed to attenuate microglial or astrocytic reactivity in the brain and did not improve motor function, clasping behavior, or weight loss. In contrast, suppressed expression of the pathogenic TDP-43 cytoplasmic protein rapidly restored motor performance and body weight, confirming the reversibility of these phenotypes in the rNSL8 model. These data further establish Axl protein upregulation as a component of the microglial response in TDP-43-driven cortical neurodegeneration but suggest that Axl inhibition after BGB treatment was insufficient to counteract neuroinflammation or functional decline in the rNLS8 mouse model of ALS.
Related
- Evaluating the Efficacy of Chitosan‐l‐DOPA MAP Gel for Acute Laryngeal Injury
- Raddeanin A is associated with enhanced anti-tumor efficacy of doxorubicin in a murine breast cancer model by modulating MDR1 expression
- Revisiting AXL as a therapeutic target in soft tissue sarcoma: dubermatinib and bemcentinib effects are largely independent of AXL inhibition
- AICAR-induced energy supply and paracrine activity of endothelial cells accelerate chronic diabetic wound healing by promoting angiogenesis and modulating macrophage reprogramming.
- Evaluating the Efficacy of mHealth Interventions in Promoting Healthy Smiles among Children: A Systematic Review and Meta-Analysis
BibTeX
@article{chen2026evaluating,
title = {{Evaluating the efficacy of Bemcentinib (BGB) in modulating Axl activity in the brain of the rNLS8 inducible mouse model of ALS}},
author = {Guyin Chen and Gizem Ozturk and Cassandra Mikkelson and Mansi Patel and Mandana Hunter and Kurt R. Brunden and Virginia M.-Y. Lee and Sílvia Porta},
journal = {Scientific Reports},
year = {2026},
month = jul,
doi = {10.1038/s41598-026-63254-z},
url = {https://doi.org/10.1038/s41598-026-63254-z},
note = {CC BY},
}
RIS
TY - JOUR
TI - Evaluating the efficacy of Bemcentinib (BGB) in modulating Axl activity in the brain of the rNLS8 inducible mouse model of ALS
AU - Guyin Chen
AU - Gizem Ozturk
AU - Cassandra Mikkelson
AU - Mansi Patel
AU - Mandana Hunter
AU - Kurt R. Brunden
AU - Virginia M.-Y. Lee
AU - Sílvia Porta
PY - 2026
DA - 2026/07/01
JO - Scientific Reports
DO - 10.1038/s41598-026-63254-z
UR - https://doi.org/10.1038/s41598-026-63254-z
AB - Amyotrophic lateral sclerosis (ALS) is characterized by progressive degeneration of upper and lower motor neurons and pathological accumulation of TAR DNA-binding protein 43 (TDP-43). Microglial activation is a prominent feature of ALS pathology, and the receptor tyrosine kinase Axl, a marker of disease-associated microglia (DAM), has been proposed as a potential therapeutic target. Here, we investigated Axl signaling and its pharmacological inhibition in the inducible rNLS8 mouse model of ALS. Disease progression in the brain of these mice was accompanied by robust microgliosis, reflected by increased Iba1 Immunoreactivity in the hippocampus and by elevated Axl protein at later stages. Treatment with Bemcentinib (BGB), a selective Axl inhibitor, resulted in central nervous system penetration by the drug and evidence of target engagement as revealed by increased plasma soluble Axl and modulation of downstream signaling pathways in the brain, including reduced total Stat3 and Akt. Nevertheless, BGB administration failed to attenuate microglial or astrocytic reactivity in the brain and did not improve motor function, clasping behavior, or weight loss. In contrast, suppressed expression of the pathogenic TDP-43 cytoplasmic protein rapidly restored motor performance and body weight, confirming the reversibility of these phenotypes in the rNSL8 model. These data further establish Axl protein upregulation as a component of the microglial response in TDP-43-driven cortical neurodegeneration but suggest that Axl inhibition after BGB treatment was insufficient to counteract neuroinflammation or functional decline in the rNLS8 mouse model of ALS.
SN - 2045-2322
ER -